Obesity 2011: Back To Basics In Bariatrics
Executive Summary
The market for obesity products has blockbuster potential, but it’s proven an elusive target for the medical device industry. The challenging regulatory environment, weak economy, and skittish investors have slowed the number of product launches in recent years, and there have been some high-profile setbacks for several potential weight loss therapies. But now, a "back to basics" movement, focused on understanding the physiological triggers behind obesity rather than simply restricting food intake, hopes to spur development of more effective minimally invasive weight loss solutions.
You may also be interested in...
Apollo Endosurgery Wants Lap-Band To Become Even More Of An Asset
At the end of October, Apollo Endosurgery announced that it would acquire certain obesity assets from Allergan: Lap-Band, one of the most well-known brands in bariatric surgery, and Orbera, Allergan’s intra-gastric balloon system, the leading such product in Europe. It’s not unusual these days for large companies to unload under-performing businesses, but the Allergan deal is striking because of its choice of partner – Apollo Endosurgery is a small organization acquiring a much larger one.
Obesity Intervention: A New Era Of Discovery And Innovation
Device manufacturers are developing several next-generation devices for the minimally invasive treatment of obesity. Many of these emerging devices not only mimic the restriction and malabsorption mechanisms involved in bariatric surgery, but are also designed to influence the metabolic responses that are key to losing weight, improving outcomes, and impacting chronic disease.
Obesity Intervention: A New Era Of Discovery And Innovation
Driven by a vast and underserved market in dire need of safer, less-invasive, more effective solutions, manufacturers are developing several next-generation devices for the minimally invasive treatment of obesity. Many of these emerging devices not only mimic the restriction and malabsorption mechanisms involved in bariatric surgery, but are also designed to influence the metabolic responses that are key to losing weight, improving outcomes, and impacting chronic disease. Indeed the obesity intervention paradigm is rapidly changing as ongoing research provides new insights into the underlying mechanisms behind obesity and bariatric surgery, heralding a new era where the primary treatment target for bariatric surgery is becoming disease specific, rather than targeted at obesity alone.